Daiichi Sankyo Co. and Boston Pharmaceuticals, Inc. have entered into a worldwide licensing agreement for Daiichi’s RET inhibitor, DS-5010, a highly selective and potent RET (ret proto-oncogene) kinase inhibitor in late preclinical development. RET mutations are associated with several types of cancer, including non-small cell lung cancer, colorectal cancer and thyroid cancer. Boston Pharmaceuticals gains worldwide rights for the research, development, manufacturing and commercializatio...